Twist Bioscience Corp (TWST) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Twist Bioscience reported revenue of $376.6M, up 20.3% from $313.0M the year before. Net income was -$77.7M (a -20.6% net margin), or -$1.30 per diluted share. Gross margin was 50.7% and operating margin was -36.2%. Operating activities generated -$47.6M of cash, leaving -$75.6M of free cash flow. At fiscal year end, Twist Bioscience held $641.9M in total assets against $168.9M in total liabilities, including $183.0M of cash and equivalents.
Open the full interactive Twist Bioscience financials → Quarterly statements, key ratios, valuation history and price charts.
Twist Bioscience Key Stats
| Share Price | $151.33 |
|---|---|
| Market Cap | $9.44B |
| Revenue YoY Growth | +20.3% |
| 52-Week Range | $25.45 – $205.00 |
| Shares Outstanding | 62.4 million (basic, 2026 Q3) |
Twist Bioscience Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $90.1M | $132.3M | $203.6M | $245.1M | $313.0M | $376.6M |
| Cost of Goods Sold | $230.2M | $285.1M | $438.3M | $462.3M | $533.8M | $512.8M |
| Gross Profit | $28.7M | $51.7M | $84.2M | $89.7M | $133.3M | $191.0M |
| Operating Income | -$140.1M | -$152.7M | -$234.8M | -$217.2M | -$220.8M | -$136.3M |
| Pre-Tax Income | -$139.5M | -$154.0M | -$228.3M | -$203.5M | -$208.2M | -$77.0M |
| Income Tax | $382,000 | -$1.9M | -$10.4M | $1.2M | $560,000 | $719,000 |
| Net Income | -$139.9M | -$152.1M | -$217.9M | -$204.6M | -$208.7M | -$77.7M |
| Diluted EPS | -$3.57 | -$3.15 | -$4.04 | -$3.60 | -$3.60 | -$1.30 |
Twist Bioscience Quarterly Results
| 2025 Q4 | 2026 Q1 | 2026 Q2 | 2026 Q3 | |
|---|---|---|---|---|
| Revenue | $99.0M | $103.7M | $110.7M | $118.4M |
| Net Income | -$27.1M | -$30.5M | -$44.0M | -$35.1M |
| Diluted EPS | -$0.45 | -$0.50 | -$0.71 | -$0.56 |
Twist Bioscience Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $93.7M | $465.8M | $378.7M | $286.5M | $226.3M | $183.0M |
| Current Assets | $334.9M | $546.5M | $596.5M | $424.3M | $346.8M | $333.0M |
| Total Assets | $398.9M | $702.1M | $961.4M | $776.4M | $614.3M | $641.9M |
| Current Liabilities | $36.0M | $63.1M | $90.7M | $73.3M | $71.0M | $91.4M |
| Total Long-Term Debt | $4.7M | $1.6M | — | — | — | $15.0M |
| Total Liabilities | $62.6M | $121.3M | $172.0M | $153.0M | $141.6M | $168.9M |
| Shareholders' Equity | $336.3M | $580.8M | $789.4M | $623.4M | $472.7M | $473.0M |
Twist Bioscience Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$142.3M | -$112.2M | -$124.4M | -$142.5M | -$64.1M | -$47.6M |
| Cash From Investing | -$114.7M | $156.2M | -$232.9M | $50.6M | -$3.1M | -$24.8M |
| Cash From Financing | $303.7M | $329.2M | $270.5M | $911,000 | $6.9M | $28.5M |
| Free Cash Flow | -$152.1M | -$139.3M | -$226.2M | -$170.3M | -$69.2M | -$75.6M |
Figures from Twist Bioscience's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Twist Bioscience financials page for every line item.
Twist Bioscience Company Profile
| Ticker | TWST |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | South San Francisco, California |
| Incorporated in | Delaware |
| Fiscal Year End | September 30 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001581280 |
Frequently Asked Questions
What was Twist Bioscience's revenue in fiscal 2025?
Twist Bioscience (TWST) reported revenue of $376.6M for fiscal 2025.
What is Twist Bioscience's annual revenue history?
Twist Bioscience's annual revenue by fiscal year: 2020: $90.1M; 2021: $132.3M; 2022: $203.6M; 2023: $245.1M; 2024: $313.0M; 2025: $376.6M.
What was Twist Bioscience's net income in fiscal 2025?
Twist Bioscience reported net income of -$77.7M for fiscal 2025.
What was Twist Bioscience's earnings per share (EPS) in fiscal 2025?
Twist Bioscience's diluted EPS was -$1.30 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Twist Bioscience generate in fiscal 2025?
Twist Bioscience generated -$75.6M of free cash flow in fiscal 2025.
What was Twist Bioscience's revenue last quarter?
In its most recent reported quarter (2026 Q3), Twist Bioscience reported revenue of $118.4M.
How much debt does Twist Bioscience have?
Twist Bioscience reported $15.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Twist Bioscience are outstanding?
Twist Bioscience reported a weighted average of 62.4 million basic shares outstanding in 2026 Q3.
What is Twist Bioscience's market cap?
Based on its latest closing price, Twist Bioscience (TWST) has a market capitalization of about $9.44B.
When does Twist Bioscience's fiscal year end?
Twist Bioscience's fiscal year end, as registered with the SEC, is September 30.
Where is Twist Bioscience headquartered?
Twist Bioscience lists its business address in South San Francisco, California in its SEC filings.
Twist Bioscience Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →